The Motley Fool··Cory RenauerCIBRA Capital Doubles Down on Amicus Therapeutics Merger Arbitrage Play
CIBRA Capital increases Amicus Therapeutics stake to 11.78% of AUM, betting on BioMarin's $14.50 acquisition for $0.20 per share profit.
FOLDBMRNacquisition13F filing